Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 2, 2009, Pages 636-647

  Shaw, Arthur Y ^a,b   Henderson, Meredith C ^a   Flynn, Gary ^b   Samulitis, Betty ^a   Han, Haiyong ^c   Stratton, Steve P ^a   Chow, H H Sherry ^a   Hurley, Laurence H ^a,b   Dorr, Robert T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [5 (4 METHOXYPHENYL)OXAZOL 2 YL] 9H FLUOREN 9 ONE]; [5 (4 METHOXYPHENYL) 2 [3 (3 METHOXYPHENYL)PYRIDIN 4 YL]OXAZOLE]; ANTINEOPLASTIC AGENT; KINESIN; NS 44636; OXAZOLE DERIVATIVE; PC 001; PC 004; PC 024; PC 026; PC 027; PC 038; PC 039; PC 042; PC 043; PC 044; PC 045; PC 046; PC 047; PC 049; PC 050; PC 051; PC 052; PC 053; PC 054; PC 055; PC 056; PC 057; PC 058; PNS 44636; PROTEIN KINASE PIM 1; TUMOR SUPPRESSOR PROTEIN; UA 62784; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GENE DELETION; GENE LOCUS; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IC 50; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PANCREAS CANCER; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA, NEOPLASM; DRUG DESIGN; DRUG STABILITY; HUMANS; KINESIN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, SCID; NECROSIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OXAZOLES; PANCREATIC NEOPLASMS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350434116     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.156406     Document Type: Article

References (33)

1. Boxenbaum H and Ronfeld R (1983) Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768-R775. (Pubitemid 14219457)
2. Burris H 3rd and Rocha-Lima C (2008) New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13:289-298.
3. Collins PJ, Hennessy LK, Leibelt CS, Roby RK, Reeder DJ, and Foxall PA (2004) Developmental validation of a single-tube amplification of the 13 CODIS STR loci, D2S1338, D19S433, and amelogenin: the AmpFlSTR Identifiler PCR Amplification Kit. J Forensic Sci 49:1265-1277.
4. Darzynkiewicz Z, Gong J, Juan G, Ardelt B, and Traganos F (1996) Cytometry of cyclin proteins. Cytometry 25:1-13.
5. Desmet CJ and Peeper DS (2006) The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci 63:755-759.
6. Funk CJ, Davis AS, Hopkins JA, and Middleton KM (2004) Development of high-throughput screens for discovery of kinesin adenosine triphosphatase modulators. Anal Biochem 329:68-76.
7. Geiger TR and Peeper DS (2007) Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res 67:6221-6229.
8. Guha SK, Wu B, Kim BS, Woonphil B, and Koo S (2006) TMS-OTf-catalyzed α-bromination of carbonyl compounds by N-bromosuccinimide. Tetrahedron Lett 47:291-293. (Pubitemid 41770816)
9. Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, and Von Hoff DD (2009) UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Mol Cancer Ther 8:36-44.
10. Hirokawa N and Noda Y (2008) Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics. Physiol Rev 88:1089-1118.
11. Holub JM, O'Toole-Colin K, Getzel A, Argenti A, Evans MA, Smith DC, Dalglish GA, Rifat S, Wilson DL, Taylor BM, et al. (2004) Lipid-lowering effects of ethyl 2-phenacyl-3-aryl-1H-pyrrole-4-carboxylates in rodents. Molecules 9:134-157. (Pubitemid 38982447)
12. Huang YS, Misior A, and Li LW (2005) Novel role and regulation of the interleukin-1 receptor associated kinase (IRAK) family proteins. Cell Mol Immunol 2:36-39.
13. Hunter AW, Caplow M, Coy DL, Hancock WO, Diez S, Wordeman L, and Howard J (2003) The kinesin-related protein MCAK is a microtubule depolymerase that forms an ATP-hydrolyzing complex at microtubule ends. Mol Cell 11:445-457. (Pubitemid 36293838)
14. Jaffee EM, Hruban RH, Canto M, and Kern SE (2002) Focus on pancreas cancer. Cancer Cell 2:25-28.
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
16. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806.
17. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, and Mukaida N (2006) Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 66:6741-6747. (Pubitemid 44085632)
18. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, and Todaro G (1975) Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15:741-747.
19. Lombillo VA, Nislow C, Yen TJ, Gelfand VI, and McIntosh JR (1995) Antibodies to the kinesin motor domain and CENP-E inhibit microtubule depolymerization-dependent motion of chromosomes in vitro. J Cell Biol 128:107-115.
20. Meanwell NA, Romine JL, Rosenfeld MJ, Martin SW, Trehan AK, Wright JJ, Malley MF, Gougoutas JZ, Brassard CL, and Buchanan JO (1993) Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid. J Med Chem 36:3884-3903.
21. Miyaki M and Kuroki T (2003) Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 306:799-804.
22. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
23. Nicolaou KC, Hao J, Reddy MV, Rao PB, Rassias G, Snyder SA, Huang X, Chen DY, Brenzovich WE, Giuseppone N, et al. (2004) Chemistry and biology of diazonamide A: second total synthesis and biological investigations. J Am Chem Soc 126:12897-12906. (Pubitemid 39372320)
24. Nislow C, Lombillo VA, Kuriyama R, and McIntosh JR (1992) A plus-end-directed motor enzyme that moves antiparallel microtubules in vitro localizes to the interzone of mitotic spindles. Nature 359:543-547.
25. Sawin KE, LeGuellec K, Philippe M, and Mitchison TJ (1992) Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 359:540-543.
26. Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR, et al. (2005) Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 11:440-449. (Pubitemid 40116865)
27. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, Pickren JW, Berjian R, Douglass HO Jr, and Chu TM (1986) Characterization of a new primary human pancreatic tumor line. Cancer Invest 4:15-23.
28. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, et al. (2001) The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7:4115-4121. (Pubitemid 34044636)
29. Vermes I, Haanen C, Steffens-Nakken H, and Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 184:39-51.
30. Wang H, Han H, and Von Hoff DD (2006) Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res 66:9722-9730. (Pubitemid 44623673)
31. Yang Z and Goldstein LS (1998) Characterization of the KIF3C neural kinesin-like motor from mouse. Mol Biol Cell 9:249-261. (Pubitemid 28084122)
32. Yen TJ, Compton DA, Wise D, Zinkowski RP, Brinkley BR, Earnshaw WC, and Cleveland DW (1991) CENP-E, a novel human centromere-associated protein required for progression from metaphase to anaphase. EMBO J 10:1245-1254. (Pubitemid 21905587)
33. Yunis AA, Arimura GK, and Russin DJ (1977) Human pancreatic carcinoma (Mi-aPaCa- 2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19:128-135.